SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as the stock price approaches all-time highs, fueled by optimism surrounding its robotaxi strategy and potential battery expansion in Europe. The community is actively debating the stock's valuation, particularly its P/E ratio, and whether it can sustain these levels. Bullish sentiment is strong, with many anticipating further gains, while bears warn of a potential pullback.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

WEEDCOIN is trending as the community rallies around its potential, touting it as "like Bitcoin but way higher." Discussions center on its cultural relevance and the broader implications of cannabis within emerging markets, with some linking it to the Solana ecosystem.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is trending amid speculation around potential marijuana reclassification following reports of a possible executive order. Community discussions revolve around the potential impact on profitability and the possibility of a significant price surge, while some caution about past reverse splits and dilution. The broader cannabis sector is gaining attention as investors anticipate policy changes and their effects on market dynamics.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

NVTS is trending as traders discuss its overnight spike and potential catalysts, with some pointing to a potential short squeeze and others highlighting its partnerships and role in AI power solutions. The community is actively debating the reasons behind the stock's recent price action and whether it's undervalued given its growth prospects. Some traders speculate on news related to a partnership with NVDA and potential breakout above consolidation.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending as community members discuss recent price drops and potential reasons, including Kepler's price target cut and speculation around FDA approval timing for their oral weight loss pill. Some traders express frustration with the stock's performance, while others remain bullish, citing strong fundamentals and potential for long-term growth, particularly with the upcoming pill launch. Discussions also involve competitive pressures from other pharmaceutical companies like Eli Lilly.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is trending as investors assess its potential following recent volatility and a dip in price, with many discussing whether it represents a buying opportunity. Community members are weighing bullish analyst target prices against concerns about valuation and a possible SEC probe, creating a debate around the stock's near-term direction. Bullish sentiment revolves around the company's growth potential and AI-driven ad platform, while bears cite overvaluation and regulatory risks.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SOUN is trending amid discussions of its potential and recent market volatility, particularly in the AI sector. Community members are actively debating the stock's future, analyzing analyst ratings, and speculating on potential catalysts like partnerships, while some express frustration with recent price declines. Others are focusing on upcoming company presentations and perceived short squeezes.

BlackRock Institutional Trust Company N.A. - iShares TIPS Bond ETF

iShares TIPS Bond ETF

Amidst fluctuating market conditions, $TIP is drawing attention as investors weigh its role as an inflation hedge, especially compared to assets like gold. Community discussions revolve around potential interest rate cuts and the ETF's performance relative to inflation data. Ray Dalio's and other institutions' strategies of including inflation-linked bonds in their portfolios also contribute to the current interest in $TIP.

Federal National Mortgage Association is a government-sponsored company, which engages in the provision of liquidity for purchases of homes and financing of multifamily rental housing and refinancing existing mortgages. It operates through the Single-Family and Multifamily segments. The Single-Family segment offers liquidity to the mortgage market and increases the availability and affordability of housing for single families. The Multifamily segment includes guaranty fees on mortgages and on multifamily mortgage loans. The company was founded in 1938 and is headquartered in Washington, DC.

Federal National Mortgage Association

Federal National Mortgage Association ($FNMA) is trending as investors discuss the potential for an IPO and uplisting, fueled by recent commentary and renewed interest from prominent investors. Community members are actively analyzing trading patterns and speculating on upcoming announcements, with many expressing long-term bullish sentiment despite the stock's volatility. Some traders cite the stabilizing mortgage rates as a potential benefit.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MLTX is trending as anticipation builds for an upcoming FDA meeting, with the community actively discussing potential outcomes and speculating on a possible buyout.  Community members are optimistic, referencing strong data and Merck's previous interest, while also watching for news and potential catalysts. Some traders are closely watching volume and share price action.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Operational and execution risks have come into sharper focus, with data center construction delays, revised timelines, and infrastructure bottlenecks raising concerns.</li><li>Financial pressures continue to weigh on sentiment, as heavy capital expenditure, a reduced forward outlook, and a speculative credit rating underscore the company’s high-risk, high-reward profile.</li><li>Retail traders and several Wall Street firms continue to bet on a rebound driven by long-term demand for AI.</li></ul>Artificial intelligence (AI) datacenter operator CoreWeave, Inc.’s (CRWV) fortunes have quickly reversed. From a high-profile initial public offering (IPO) in March this year and a meteoric two-month rally that kicked off in late April, <a href="https://stocktwits.com/symbol/CRWV">CoreWeave’s stock</a> has lost much of its momentum as skeptics sowed doubt in investors' minds, who were&nbsp;going all in on&nbsp;any AI play.Even so, the stock is still sitting on handsome gains. What has changed is that much of the nearly 370% return it generated at its intraday peak in late June has evaporated, leaving loyal investors wondering whether the heydays will return.<img src="https://news.stocktwits-cdn.com/CRWV_YTD_Stock_Trajectory_png_d7bd286a31.webp" alt="CRWV YTD Stock Trajectory.png">Source: Koyfin<h2 class="st-heading-2">What Precipitated the Down Move</h2>CoreWeave's hot post-IPO rally stalled after the stock hit a peak in late July.&nbsp; As investors paused for a breather, the Michael Intrator-led company spooked investors by announcing a $9 billion all-stock deal to buy Bitcoin miner Core Scientific, which had also branched out into AI data centers. The agreement has since then been shelved. An expanded AI cloud deal with OpenAI, valued at up to $4 billion, helped to reverse the downtrend. The rally attempt fizzled out in mid-August despite second-quarter results that outperformed expectations. Some blamed the stock slide on the bigger loss it reported for the quarter.&nbsp;After a modest recovery from the post-earnings slide, CoreWeave moved sideways, before the third-quarter earnings report, released in early November, triggered another round of selling in the stock. A delay in the data center infrastructure coming online prompted the company to reduce its forward-looking guidance, exerting downward pressure on the stock.Following the Q3 report, Macquarie analyst Paul Golding, who remains on the sidelines of the stock, cut the price target to $115 from $145. The analyst attributed the action to the use of a lower valuation multiple to reflect the persistently high capital expenditure (capex). He, however, sees room for earnings improvement.Capex, however, declined in the third quarter due to delays at a third-party data center developer, pushing the delivery timeline for "powered shell" capacity.<figure class="table" style="width:94.66%;"><table class="ck-table-resized"><colgroup><col style="width:31.52%;"><col style="width:20.9%;"><col style="width:25.56%;"><col style="width:22.02%;"></colgroup><tbody><tr><td>&nbsp;</td><td>Q1'25</td><td>Q2'25</td><td>Q3'25</td></tr><tr><td>Capex</td><td>$1.9B</td><td>$2.9B</td><td>$1.9B</td></tr></tbody></table></figure>&nbsp; &nbsp; &nbsp; &nbsp; Data source: Earnings call transcriptThe losses were exacerbated by the AI pessimism that was beginning to grip the market around that time. The recovery seen since late November proved short-lived, and the stock has been in a five-session losing streak since Dec. 9.<img src="https://news.stocktwits-cdn.com/CRWV_YTD_Returns_png_7091a212f6.webp" alt="CRWV YTD Returns.png">Source: KoyfinCoreWeave now has 41 data centers, with eight of them coming online in the third quarter. The data center capacity corresponds to 90 megawatts of active power and 2.9 gigawatts of contracted power, according to an S&amp;P <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/3492923">report.</a> The firm sees looming risks if the company faces construction or performance issues arising from the data center infrastructure, potentially coming online later than planned.S&amp;P rated CoreWeave's $2.25 billion 1.75% senior unsecured convertible notes, due 2031, a 'B' — suggesting speculative or junk grade. The Recovery Rating is '5,' indicating a low probability (30%) of recovery.&nbsp;<h2 class="st-heading-2">Delays Dent Progress?</h2>In an exclusive report published on Tuesday, the Wall Street Journal<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/tech/ai/coreweave-stock-market-ai-bubble-a3c8c321">&nbsp;said</a> unexpectedly turbulent rainstorms in North Texas caused a roughly 60-day delay at a construction site in Denton.The data center cluster, with 260 megawatt computing capacity, which CoreWeave planned to lease to OpenAI, is now pushed back several months, the report said. It is also noted that revised design plans have delayed some of the data center projects that one of the company's partners was building for it in Texas and elsewhere.<h2 class="st-heading-2">Short Attack</h2>Following the Q3 report, short seller Jim Chanos piled on misery to the stock by <a href="https://stocktwits.com/news-articles/markets/equity/jim-chanos-joins-michael-burry-in-sounding-ai-alarm/cLPIZeRRE59">questioning</a> the company's accounting practices, including its use of a longer depreciation period. Even with a longer depreciable life, CoreWeave's third-quarter numbers suggest the company is barely profitable, he said in a post on X.&nbsp;<h2 class="st-heading-2">What Retail Traders Feel About CRWV Stock</h2>After the stock slump, CoreWeave retail investors have shed their cautious stance and have jumped onto the bullish bandwagon. On Stocktwits, retail sentiment toward the stock was 'bullish' as of early Wednesday.<figure class="image"><img style="aspect-ratio:735/436;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_17_at_12_24_16_AM_png_b341e134f4.webp" alt="Screenshot 2025-12-17 at 12.24.16 AM.png" width="735" height="436"></figure>&nbsp;A retail trader hinged his <a href="https://stocktwits.com/Cybermoon/message/639390500">expectations</a> on a potential "V-shaped" recovery in the stock following its five sessions of losses in a row. Another user hoped for a short-covering rally. According to Koyfin, short interest in the stock is elevated at 6.60%, down from the September highs of 11%.<img src="https://news.stocktwits-cdn.com/CRWV_short_interest_png_72b08cfb62.webp" alt="CRWV short interest.png">Source: KoyfinMore than half of the analysts covering the stock have 'Buy' or 'Strong Buy' ratings, and 11 remain on the sidelines, and only 2 have sell-equivalent ratings, according to Koyfin's database. The average analyst price target for the stock is $130.96, implying nearly 90% upside from current levels.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:<a href="https://stocktwits.com/news-articles/markets/equity/how-ford-and-gm-stocks-quietly-beat-tesla-and-rivian-this-year/cLeJfyRREYw">&nbsp;Detroit Strikes Back: How Ford And GM Stocks Quietly Beat Tesla And Rivian This Year</a>

CoreWeave logo is displayed on a mobile phone, with the company's branding visible in the background, in this photo illustration in Brussels, Belgium, on November 10, 2025. 

CoreWeave’s Post-IPO Surge Fades: Investors’ AI Fears Leave Stock In A Tight Spot

Heavy capital spending, data center delays, accounting scrutiny, and waning AI enthusiasm have weighed on CoreWeave’s shares, even as retail traders stay bullish and analysts still see meaningful upside.

Equity

Heavy capital spending, data center delays, accounting scrutiny, and waning AI enthusiasm have weighed on CoreWeave’s shares, even as retail traders stay bullish and analysts still see meaningful upside.


<ul class="summary-bullets"><li>DFLI shares will start trading on a split-adjusted basis on December 18.&nbsp;</li><li>The company will trade on Nasdaq under the same ticker.&nbsp;</li><li>Following the reverse split, DFLI’s outstanding shares will reduce to about 12.1 million from 120.8 million at present.</li></ul>Shares of Dragonfly Energy Holdings Corp. (DFLI) tumbled over 44% in Tuesday’s premarket trade after the company announced a 1-for-10 reverse stock split.DFLI stock will begin trading on a split-adjusted basis on December 18 and will retain its current ticker on Nasdaq.After the reverse stock split, DFLI’s number of shares of common stock outstanding will reduce to about 12.1 million from the current 120.8 million, the company said.<h2 class="st-heading-2">Split Details</h2>The battery technology company’s shareholders approved the reverse split on October 15 at an authorized ratio in the range of 1-for-2 and 1-for-50 and its Board approved the 1-for-10 reverse split on December 2.“Recent capital raises and debt restructuring have materially strengthened our balance sheet and improved liquidity. With a more durable financial foundation, Dragonfly is focused on scaling revenue, deepening strategic partnerships, and investing in differentiated battery technologies that support long-term value creation,” said Dr. Denis Phares, Chief Executive Officer of Dragonfly Energy, clarifying the company’s future goals.Dragonfly Energy is primarily a lithium battery maker, most known for its Battle Born Batteries brand. Earlier this month, the company partnered with National Railway Supply to power the firm’s first lithium battery line. The announcement came after the American Railway Engineering and Maintenance-of-Way Association released its first lithium battery standard.In November, <a href="https://stocktwits.com/symbol/DFLI">DFLI</a> reported third quarter (Q3) 2025 results, posting $16 million in net sales that marked a 25.5% increase from the previous year. The company’s gross margins grew 710 basis points to 29.7% although it reported a net loss of $11.1 million, up from a loss of $6.8 million in the previous year.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, the retail sentiment around DFLI remained ‘bullish’ over a week, and message volume climbed to ‘normal’ from ‘low’ levels at the time of writing.<img src="https://news.stocktwits-cdn.com/Screenshot_2025_12_16_at_7_15_54_PM_png_2aff3d75b8.webp" alt="Screenshot 2025-12-16 at 7.15.54 PM.png">One user shared their ‘bullish’ stance on DFLI, noting that the stock seems oversold compared to its market capitalization.<stembedurl>https://stocktwits.com/JBankes/message/639284631</stembedurl>Shares of DFLI have plunged more than 78% in the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

In this photo illustration, the Dragonfly Energy logo is seen displayed on a smartphone screen. 

Why Did Dragonfly Energy Shares Plunge 44% Today?

Shares of Dragonfly Energy Holdings Corp. (DFLI) tumbled over 44% in Tuesday’s premarket trade after the company announced a 1-for-10 reverse stock split.

Dragonfly Energy announced a 1-for-10 reverse stock split on Tuesday. 

Illustration showing chimeric antigen receptor (CAR) T cells (blue and green) being used to treat non-small cell lung cancer (NSCLC). | Representative image: Getty Images

Why Did Aethlon Medical Stock Tumble Over 12% Today?

Aethlon Medical's stock drew investor attention after the company announced a private placement and warrant inducement deal. 

Rising stock market chart on a trading board background.

Entero Therapeutics Stock Jumps After Company Rebrands As GridAI Technologies Corp.

The name change follows the company’s acquisition of GRID AI Corp in October.

<ul class="summary-bullets"><li>The company expects gross proceeds of about $60 million from the offering, which it intends to use for general corporate purposes.</li><li>Pasithea expects the offering to close on or about December 1.</li></ul>Pasithea Therapeutics Corp. (KTTA) on Friday announced the pricing of a public offering of 80 million shares of the company’s common stock at $0.75 per share.KTTA shares traded 43% higher on Friday morning at the time of writing.<h2 class="st-heading-2">Offering Proceeds And Purpose</h2>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/28/3196323/0/en/Pasithea-Therapeutics-Announces-Pricing-of-60-Million-Public-Offering-of-Common-Stock.html">expects</a> gross proceeds of about $60 million from the offering, which it intends to use for general corporate purposes such as ongoing research and pre-clinical studies, clinical trials, the development of new biological and pharmaceutical technologies, and investing in or acquiring companies that are synergistic with or complementary to the company’s technologies, among others.The offer price represents a 29% discount to the stock’s Wednesday closing price.The company said that it expects the offering, led by investors including Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners, and Squadron Capital Management, to close on or about December 1. The offering will extend its cash runway through at least the first half of 2028, it added. &nbsp;Earlier this month, the company was awarded a Hoffman ALS Clinical Trial Award grant worth about $1 million to study its lead drug candidate, PAS-004, in Amyotrophic lateral sclerosis (ALS) patients. ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord, where patients eventually lose the ability to breathe.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/KTTA">KTTA stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.A Stocktwits user opined that the stock will erode its gains to hit $0.75 level.<stembedurl>https://stocktwits.com/GABBYGIRL/message/637652497</stembedurl>KTTA stock is down by 52% this year.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/china-byd-recalls-nearly-89000-evs/cL5aGIxRELP">China’s BYD Recalls Nearly 89,000 EVs – Regulator Cites Battery Output Concerns</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Why Did KTTA Stock Soar A Whopping 43% Today?

The company announced the pricing of a public offering of 80 million shares of its common stock and said that the offering will extend its cash runway through at least the first half of 2028.

<ul class="summary-bullets"><li>The company has now proposed an early-stage clinical trial to evaluate the cell therapy.</li><li>Lunai is also advancing additional studies and expanding the clinical reach of its DCCT platform through collaborations with investigators in non-small cell lung cancer and prostate cancer.</li><li>The company is also preparing for formal licensing negotiations and pursuing activities ahead of the commencement of human clinical trials in early 2026.</li></ul>&nbsp;Shares of Lunai Bioworks (LNAI) jumped 26% in the pre-market session on Tuesday after the company announced that it has secured its first letter of intent (LOI) to license its next-generation immune cell therapy."We are seeing accelerating validation from both researchers and industry partners," <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/lunai-bioworks-secures-first-licensing-loi-following-landmark-breakthrough-showing-complete-tumor-regression-in-humanized-cancer-models-302624947.html">said</a> CEO David Weinstein. He added that the early licensing activity reflects growing confidence in the platform's potential to unlock scalable treatments.<h2 class="st-heading-2">Data For Cell Therapy</h2>The cell therapy, Dendritic Cell Combination Therapy (DCCT), achieved complete regression of both primary and metastatic pancreatic tumors with no recurrence in humanized preclinical models.The company has now proposed an early-stage clinical trial to evaluate the cell therapy, manufactured from healthy donor cells and stored ready-to-use, across several high-risk tumors, including pancreatic cancer, which has a poor survival rate.<h2 class="st-heading-2">Plans Ahead</h2>Lunai is also advancing additional studies and expanding the clinical reach of its DCCT platform through collaborations with investigators in non-small cell lung cancer and prostate cancer.Additionally, it is preparing for formal licensing negotiations and pursuing activities ahead of the commencement of human clinical trials in early 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around LNAI jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.<a href="https://stocktwits.com/symbol/LNAI">LNAI stock</a> is down by 85% this year and by about 75% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-experimental-glp-1-drug-shows-weight-loss-blood-sugar-level-reduction-in-study/cL52hCvREXo">Novo Nordisk’s Experimental GLP-1 Drug Shows Weight Loss, Blood Sugar Levels Reduction In Study</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

 In this photo illustration, the Lunai Bioworks logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

LNAI Stock Soars Pre-Market After Immune Cell Therapy Gains Licensee Interest 

The cell therapy, Dendritic Cell Combination Therapy (DCCT), achieved complete regression of both primary and metastatic pancreatic tumors with no recurrence in humanized preclinical models.

<ul class="summary-bullets"><li>If the proposed bidding process is approved, interested parties can submit binding offers to acquire Clearside’s assets in whole or in part.</li><li>CEO George Lasezkay said that the company has “attractive assets,” including its SCS Injection Platform.&nbsp;</li><li>The company has also filed several motions to enable normal operations during the process, it said.&nbsp; &nbsp;</li></ul>Clearside Biomedical, Inc. (CLSD) said on Monday that it has filed a voluntary petition for Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware.Shares of the company traded nearly 69% lower at the time of writing.<h2 class="st-heading-2">What Does The Company Intend?</h2>The biopharmaceutical company is <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/24/3193383/0/en/Clearside-Biomedical-to-Pursue-Strategic-Sale-of-its-Business-Through-Voluntary-Chapter-11-Process.html">seeking</a> authorization to pursue an auction and sale process. If the proposed bidding process is approved, interested parties can submit binding offers to acquire Clearside’s assets in whole or in part."Our Board of Directors and management team have thoroughly assessed all of our strategic options and believe that this Chapter 11 structured process represents the best possible option for Clearside and its stakeholders,” said CEO George Lasezkay.Lasezkay also added that the company has “attractive assets,” including its SCS Injection Platform, which is a proven in-office, repeatable, non-surgical procedure for the targeted delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.The company’s CLS-AX clinical development program is also up for sale. CLS-AX is being developed for the treatment of serious back-of-the-eye diseases, including neovascular age-related macular degeneration (wet AMD) and diabetic retinopathy.The company has also filed several motions to enable normal operations during the process, it said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around CLSD jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:587/60;" src="data:image/png;base64,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" width="587" height="60" alt="CLSD’s Sentiment Meter and Message Volume as of 11:21 a.m. ET on Nov. 24, 2025 | Source: Stocktwits"><figcaption>CLSD’s Sentiment Meter and Message Volume as of 11:21 a.m. ET on Nov. 24, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/CLSD">CLSD stock</a> is down by 94% this year and by about 95% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/oscar-health-stock-soars-on-reports-of-two-year-obamacare-subsidy-extension/cL5bB5mREQ7">Oscar Health Stock Soars On Reports Of Two-Year Obamacare Subsidy Extension</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

 In this photo illustration, the Clearside Biomedical logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CLSD Stock Plummets After Company Files For Bankruptcy Protection

The biopharmaceutical company is seeking authorization to pursue an auction and sale process.

In this photo illustration, the Tempest Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

TPST Stock Plummets After Inking Deal To Acquire CAR-T Programs From Privately-Held Firm In All-Stock Transaction

The transaction is expected to close in early 2026, provided it receives all required approvals. 

<ul class="summary-bullets"><li>The January meeting is intended to discuss the clinical trial design, patient population, and a potential approval route for Buntanetap in PDD.&nbsp;</li><li>According to Annovis, PDD affects approximately 30% of Parkinson’s patients.&nbsp;</li><li>The company also said that its late-stage Alzheimer’s Disease study is ongoing with full regulatory alignment.</li></ul>Annovis Bio, Inc. (ANVS) on Tuesday said the U.S. Food and Drug Administration (FDA) has scheduled a January 2026 meeting to discuss the company's pathway to developing Buntanetap for the treatment of Parkinson's disease dementia.Parkinson's disease dementia (PDD) is a type of dementia that occurs in people who already have Parkinson's disease, characterized by cognitive decline, such as memory problems and slowed thinking, along with the movement issues of PD. According to Annovis, PDD affects approximately 30% of Parkinson’s patients.<h2 class="st-heading-2">What Will Be Discussed At The Meeting?</h2>The meeting in January is aimed at discussing the clinical trial design, patient population, and a potential approval route for Buntanetap in PDD, the company said. According to Annovis executive Cheng Fang, PDD is a natural extension of the company’s Alzheimer's and Parkinson's programs, wherein the company generated data demonstrating meaningful cognitive improvement with Buntanetap."The scheduled January meeting marks a key milestone for our pipeline, underscoring buntanetap's potential across multiple neurodegenerative indications and the strength of our scientific approach." Maria Maccecchini, CEO, Annovis<h2 class="st-heading-2">Alzheimer’s Trial Progress</h2>The Malvern, Pennsylvania-headquartered company also said that its late-stage Alzheimer’s Disease study is ongoing with full regulatory alignment on study design, endpoints, and patient population.The study is set to support applications for the drug in symptomatic treatment and disease-modifying treatment with Buntanetap.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2><a href="https://stocktwits.com/symbol/ANVS">ANVS shares</a> traded 16% higher at the time of writing. On Stocktwits, retail sentiment around ANVS remained in the ‘extremely bullish’ territory, while message volume remained at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:624/61;" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAwsAAABMCAYAAAAiEyvzAAAQAElEQVR4AeydC1xU17X/f8NDBgZhIKIzRqukJgLRKMY0kSQ3CcbcP/gxVdGYQqsfAWlUTGsl7SeN6etqbj+p1N76SqKYxhQaa0RbK/SvERNN1BiV5GIAlQAGdFCQGZDHIA/vXmdmeAwzMAPDa1jjbM45e6+99t7fc1zr7Mc543KXP0yACTABJsAEmAATYAJMgAkwAQsEXMAfJsAEnIgAN4UJMAEmwASYABNgAo4jwJ0Fx7FkTUyACTABJsAEHEuAtTEBJsAEBpgAdxYG+ARw8UyACTABJsAEmAATYALDg8BQbKXNnYW6Oj0qK6tw48YtXL9ezoEZ8DXA1wBfA4PwGiAbTbaabHZ/OiUqj8ql8tlHsI/ka4CvAb4GBuc1QDaabDXZbFt9RLedBVJGivX6BsjlHhg1yg9q9SiMHRvAgRk4+TXA1zj/Px9a1wDZZrLRZKvJZpPtJhtuq0PoiRzpp3KoPCqXyqd68LUztK4dPl98vvgacP5rgGwz2Wiy1WSzyXaTDe/O9nfZWaiqqkFtbT2USh/4+/vCy0sOV1cXyGSy7vRyOhNgAkyACfQzAZlMJtlostVks8l2kw0nW44++JBe0k/lUHlU7qD2EX3AgFUyASbABIYKAZlM1iMf4QIrH3ICzc3NYiZBCQ8PdytSHM0EmAATYAKDlQDZ7lGjlCBbTjbdkfUkfaSX9FM5jtTNupgAE2ACthBgmd4RINtNNpxsOdl0a9osdhZoSuLOnUb4+fnwLII1chzPBJgAExgCBGQymWTLyaaTbXdElUkP6WMf4QiarIMJMAEmMHAEZLLufYTFzsLt27Xw8fHmjsLAnTsnLJmbxASYwEARkMlkkk0n2+6IOpAe9hGOIMk6mAATYAIDT0Am69pHdOos0IiRu7sbLz0a+HPHNWACTIAJOIwATTeTbScb3xullJ/0eHjw8tTecOS8TIAJMIHBRKArH9Gps0BPR9NT0oOpAVwXJsAEmAAT6D0Bsu1k43ujifKTnt7o4LxMgAkMPgJcIyZAtp1svDmJTp2FxsYmMaswwlyOj5kAE2ACTGCIE/DwGAGy8b1pBuUnPb3RwXmZABNgAkxg8BEg20423rxmnToLzc0tcHHhV6Oagxpcx1wbJsAEmID9BMi2k423P2dbDspPetpieI8JMAEmwAScgQDZdrLx5m3p1FkgAZmMOwvEgQMTYAJMoF8I9FMhMpljbLtM5hg9/dRsLoYJMAEmwARsICCTWbbtFjsLNuhjESbABJgAE2ACTIAJMAELBDiKCTgTAe4sONPZ5LYwASbABJgAE2ACTIAJMAEHEuDOAhxIk1UxASbABJgAE2ACTIAJMAEnIuAcnYXqUly8rHWi08JNYQJMoMcEOCMTGMoErp7BwQNnUDKU28B1ZwJMwKkI9ElnobbgE3zw1lZs3izC/+zA7gPZuNnoKG6lOGVmSAtOHsLRzE9x0VFF2KuHjPupUntzsTwTYAJMYPgRKD+D1Ld2YndWZ5uZn7Eb29/KRP5QpdKYg4Nv7UZmgXkDynBiz058eK7OPKHzsa4MRcVlqOycMmxjuOFMgAkMLAHHdxYqz+DDw7lA6HwkJCZi1Q8j8SByceLrase0VFeKK2aGdFJELGLjIzHFMSXYraWq9BsUXeeZDbvBcQYmMIgINDc3Q6+/g5qaOmi11aio0OHmzUrcuHELGk0Frl8vl7Z0TPGUTnIkT/ko/yBqzuCtSlMDGhqbUHs5F0Xta9lyGfmFdWioF+nt44fSvvsDUPvUoajgasdaVwofccsLYyd5dYznIybABIYMAbLxZOvJ5pPtJx9AvoB8grP7CAd3FsQ5LylDpedkPP7oOCjcAY97JuDRBTFYNN1HJJq+zagszMX5C9m4WKhFkylabBuqq1FLsxC0tEikn88pRVWLSKBvYx2qblajQeTQ66pRpasTeyKhsQFobtPSScelcoNcSzVKcrJFuZc7z3S0NEBzidKyka8R+oRaw7cZtaKsBlGHphuXRV4hY9InBJpqq1F+W8gLB1gl5Kpqm0Usf5kAExjsBO7evSs6Bw3Q6W6jpeWu6BRUorKyCtXVtagXN6x37jSiqakZ9M5pkqX20JaOKZ7SSY7kKd+NG5WguOrqGmlL8hysEJAHIMD9KvKL26XniM7DKBVGt4sy7DZb9RdoLEc++QkR8m90tL1VVw0+poMPIYXCj5QYbf3Fq50HsRo0JjsvfA/ZdBEkn0R5rfoJSqTggaAJfmi4VgwNHRpDVV4xKv0nIkhpjGinx1IdjFKGTUM1OvqVZskntdZJtKeqWvggNOOm1K5clBibZfJZlspoqryKi4Lb+ZyrqCSfayiN/zIBJmAkQPaefs1Yxz4Cju8sKH2gqL2Ezz433qAbobdttDj/wTt471gOSq6W4qtjH+CdA7miA0ASZfhs3x4c/MchbE/7BPlXhdHOOog9/zCmF3yC1I++QS3KcPaDvUj94BPQbK/ms4PYve+M0Ti36XhHpOeLTsnn/96LPf8+h8z39iLrUinyzx9B6rtHUCQ6AFQq6q/i6Ls7ceDMVVGnq/j8wG7sPlkmJQG5yHz3Qxz4xx7s+Gc2Skz6jhvSCz7eiyNX6oAbX4j67EXqx98Y8/GGCTgBASdsQkPDHWnmoKzslugcVKOuTi86BM1wd3frVWvd3FxFJ6FJzEzUS7MSpL9adDyoI9Irxc6YucYNowM9UJBz2di6BpzPK4V6vNp4bNporfuL+lwcfHsvThRWi5vnUmG338PBSw1SRs3xPdh9OBvXa+twMycLe/76mWFZT+ERbN/+Ho6eLxW2/jJOHRRyRltOGTVZe7D9QLa4eW5G5flM7H7/Q2Qe/wRfXRepXfoJkW78+j74XfhXl6JIZ4wQ3i3/qhb+94XAn6JqvxE+ZSc+OHFZ1OEqzh+mMnOEX6PEzkHyb5litr41KVfk34PWqNwj2L33EA7u2Y1/iXbln8/Ch3sO4sTJD/GO0WedEO1MPSv8lFFH5bkPseP9Y/hK+OCSnGNI3XkIF+uNibxhAsOcAPuIzheA4zsLE8Ix73v+qDyzF1veSsWhz8XojOmmXJRf+VkGTtROxotxSzB/wTzExM3G2NJz+EwjEo3fypZxiEkQsxELliDhuQlAsZieprTgCKxaEAJfjMN/vLQCq16KQBDFWwikY0m80LEoBgum+qDqyiUonluBZYtEmT98DKNrryL/W0PG/I8ykD/yKSxbNh/zF8zHshcfguuFM/iqtd51qFOEY+WKJZgv9L04ww9VhZekzknQ3BVY8KCYNbn3CVEfUae5DxiU8l8mwAQGFYHa2nppWdGtW1XSzAGNGpkqSM7Bw2OE6bBHW8pPekyZW1paQNPVNEVdVVUjZi9aDYpJZFhv7wmeAEXxJeQTFnHjf+WGCvff2yRurduwdOkvLl9G0YgQRCx6Cv8RPg/LXorF/MkeInMZ8kQHQv3Yi5j35OOIiF6KNUsfN9yo3/cEYpavRGz0PGHrl2DZrABUXfpfFIlcNDD0eU4DgiKXYM6jMzEn+jkEuTdAMXUewiYA3fsJSQmgnIxAfy2KLjcYIupzUHDDB+Mn+YE++VlHkO8+E8vIn5C/WfYURl/7BIfOGeVJyN5QUwfFM7FSu2LinsL45lJcrHzIUIbwWRGCy82CXImtcM449FkdghbFIkb44PnRsZhzbynOni6zt1SWZwJORYB9hPXT6fjOgihL/fgSceO8CHMeUEBz5iB2b9+LU9dEAqqR/40WinsnwKu6GlU6Eap94O9bjcqblG4IilFq+JpqRjMVhmi7/rbXob7HB/Aah/vvNarw9ICHMJu1VXR8GVeKmxEwYQKaqD4UXPzg616NWzco3RB8xoyDm2EX/j4K4x5vmAATGOwEGhubUF6uBd2w0/IhS/Wlm3wPD3dLSTbHjRjhJmYWGjvJU6eEnBAtU7p9uxZ03EloOEaoH8Ikn1LkXwIavv4Gmnsn42GP9iC68RfjVfAXnYzMA+dQVNl+CZIKY0e7Ct/zIY7mlIGWkLZp9YKvjyjv1lVcPHkEmYW1cKuvE56JJJrR1OIKt9bLwAMe7s1oqKU02/wESQJ+uH+8D25+e1k6bPi6GDd9JiBYmjS5iqJrzRgdFApploEkFFPx8CQPaAoN8hRlf/DB6PGuhmwuAfD3BkZPfAAKQwzkIwTY+lppdqUq7xtUeqkQqKhGFfk7EXyFn62qLDdK84YJDC8CQ9xH9MvJMt2SO74wDxWmhM9HwqoleNS/Ep8fO4Mq1EEvfGnDtWwcF1O7hvAFKkdOwFil46tgm8YGNDQBlZc+aVenbwD1OIz2tE0DSzEBJjD4CNy9C1AHgToK5Ay6qiE9a+Du7taViA1pLl12BKiTcPt2HWimgZ51sEGhk4v4YdokHxR9fQ5fFpQj8MGpZu3txl/4P4Zly+dj2ohLyHx/h7R0tUC6sQeC5iUg5kkVqs4ewPYtu3HwS61Bd+1lHNq5A+8cPIMSBCAoeBzEbbQhDVMxZVID8k+eQ4m4gS75/FN8XT8BQdJksX1+Qi1mTXyvfSPNTucXl8E3cDKkvgKqISa44OHRVioVLt3M365EuzEziu6TUNcgOlb6Mpxr9cGf4PNKHwSO9euT8lgpExisBNhH2H5m+q6zYKqDewDCHhRmslqLcqhwz0jA9d5HxBQwTQO3BZrmNWXp320AfL0B36DnzOoUjikD1oHpXwJcWj8R4GL6jQC9taKiQgsa0belUHIa1KEYMcLdFvFOMtTRaGxs7BRvKaKl5S7oTRo63e0uOxeW8jpbnO+MyRit+QJnK8YhaLJ562zwFz7j8OjcGKwSg1JTmnKQmXXZqMQVo6c+hUVxKxH7bABuHs/AKR1w8cgRFI+ejTVxSxDxZCiCRnu0zhhTRl+FAgqXcpwXN9LnK9SIWDoPU6RBIzv9hPq7GO+pwbdXLuNbjRfGf1dF6kUQo/4+QK3wh+Kg9XuzshrwD8Do1hiznRaz414cqv29AHcVHl3Q5n9pSfD8sHG90MpZmcDQIsA+wr7z5WKfeHfSzcg/sBO7D+ei9YVCjeU49bUGbqpxGC+yBz04Ac1iFP9oiRjdEMf0rSJDSTu2BDcSqkWVw15CrRKjSWLK+GwmvhL2mrQDzaisrDPs2vDXVSaEaqulKV6xx18mwAQGkAAtKbp5Uwu6+benGpTPo4fPLVA+ym9PefRgdXm5Tnrjkj35nErWcyqCAprhOukhBFnwRl36i8JcXDTZbHd/+I90NaLRIv+rUjQZj3xH+7fOHjQLt+PqZpRrqUbBV1fFjLdREGXIK2rC+FkRhoGjuY9jko8pTWXRT1j3E+Mw6TtuKDnzBUo8JiJoQpue6UF+qPzqk1Z/01SShfPXXDEpJMQgZKqf4Qj+3h7AjWJcpL4o1fnf2SixwMoo3v1mcggCmy7j+EdtjCA6L1UO7JB0XwmWYAIDR4BsNfsI+/j3xuRYKMkVQbPDMfH2Z/hg+1bDj7Jt24827gAAEABJREFU3YsvEYKIiKmSwfZ4cB4WzfTClfQd2LJ9p5gi3oo9/ziHIluf7Qp4BA+Pr8Z5Me28ZctenKpBrz/qZxYhIrAaJ97dii1v7cSW/9mBDz7Ktfnmf/T3QjH+djbe2yLalHYGxpnwXteLFTABJmAfAVreQw8w05If+3ICen0jevrcgmFmwXR7anvJTU1N0vMU5Lxsz+VMkh54+MVErPp/rXfTHRrXlb+obbiKs+8Jm01+ZOsOHK2YiDnhDwAtDajMy5Ts+Hay52m5cPvebISJmeJpMx6AW0EmNm8Vdn77h7ioCIB/a4kq3C9GtC5+aPRdmw26dx/IQWULYK+fCKQeQqUWbhMfgFDbWor/4wuEv6lEVgrpFz4j/Rt4zXoR80wzK/cGYLRLKbIO5Ep5PKZORaDrVRzdKuolfN7nI0MxxVtK6tkfzxDMXzATXgUHsWWL8MHbd2Dze4dwtrihZ/o4FxMYQgS68RFdtmQ4+wiXLsn0JNHnuwh/cQXWJsYidvlSxK4SjiD6KUxStClTP74Iq9aswNLoJYiJXYk1y8MRKAZPABXC4xIRG26ashV51E8hdu18TBO7hq8Xpi0SeeJjEPvSEoR5A+rwpVgb95RxTagFHdPmt0snLVOxaG0iFk2jfQpeCJq7FGtWxWLpi0uw9CVR5xdmGp2IuayQnza/oz6FkElciYQfLcPK6MfQrqlCmL9MgAn0B4Hbt2ul5T09LYtu3N3EqK5MRlOFtmuRyWS9Wk5EHRvq4NTW6m0vdChLdrLp7RpjIc2av1AERyB2TSISfij8yNIVWLsiAkFkfF1UCCMftGoZYoQ9j121AjGPG33Kfc8hQdj5WJGHtvOfjMAyk3+pz8X5Yh+EJwhbTr5LhKWLQ+FV+glO5FEdu/ITlG4WJj6HVcLPJDw3ziyB9MRKPnJpdIzkC1/8nl+bjPIxxFAdn5tsiKOb+1UrkSDqkyC1ZSrmCD/Z6r+mCX9kaoOUw+ADW9NFnLqDjxQR9z6GF8nPLRPsopdhzZqlmHOfh0jgLxNwXgLsI3p+bl16nrWbnO5e8FX6wNea/XHxMKQrjFPCsO/jpvCBwt2+PN1Kd1fnLhW4QqH06rD+tUtxTuwdAc7NBNoRoN8zoIeH20X1aJeWLnl7e0Kh8ISv70jcc48So0f7Q6W6B2PHBkhbOh41SgmlciRMsrT+tUcFtstUVXVbeqVruyjeNRHowl94+Ag/42PB0RjteSc/YYz3MPd+9CpWmT9GC5+kIN8lBS/I4QrX9uqN+a36NlOdu9sa9XSqB+WjNFEP2jUE8i8+Dvd5EjulF/stA2T+68QE2Ef07uS69C4752YCTIAJDCwBeuNRTY3tzxiZ19bNzU10DLxFR2AU6NmDkSMV0rFCIRfH7qDZBhcXg6mkLR3Tg9BeXnL4+HiLoADlGTPGX9qSDHr4oQefh+uSpB4ic1y2qY9hmtslfJiyFwcPHBJhL3a//Rlqp89DxCTHFcOamAAT6F8C7CN6z9vgAXuvhzUwASbABPqdQE1Nvc1vPDKvHN3w+/v7iJkDP2kmwcXFvuVH5vpcXV1FZ8EL1Gnw9fWGq2vPzGtlZfXwfujZHGx/HbuoEL48AbHPP4ZJE8Zh0rRwLPnxCsQ8OY5H3vvrHHA5zkRgULSFfYRjTkPPvJljymYtTIAJMIEeE6AR+Opq+99wQDMD99zjC1pKJJd79Lh8axllMpnU+Rgz5h5phkImk1kTtRhveoaBXrFqUYAj+5CAKxQBEzBlRiim3Bfg8GU/fVhxVs0EmIAZAfYRZkB6ccidhV7Ac5qs3BAmMMQINDe3gEbg7a02dQ4CAvxAy43szdsTeYXCE1QedVDsyU/PQNCSJHvysCwTYAJMgAkYCLCPMHBw1F/uLDiKJOthAkyg3wjoevCDZvRcAS07ksnsG+nvbaOoo0AdBns7KDQqZuuPypnXkY+ZABNgAsOZAPsIx5597iw4lidrYwJMoI8J0I+Z0Y20PcX4+flIzxPYk8eRsjKZDLT0iWYa7NFbXV3Lzy/YA4xlmYBzEuBW2UGAfYQdsGwU5c6CjaBYjAkwgcFBgH44TS4fYXNlqKPg6en4ZxNsrkA7QXrweeRIr3Yx1ndF/wIKhbzHD0pb18wpTIAJMAHnJcA+wvHnljsLjmbK+pgAE+gzAvX1DaDRdl/pNxB8pdeadlWYr683BktHwVTPkSMVoNeumo4tbWnJUkCAP3Qt9XjpwFZ8XJhjSYzjmAATYAJMoB0B9hHtYDhwlzsLDoTJqpgAE+hbAvQLnOQMbt6sxJ07TdLDw/RbB5Zee0o35AqFZ68r1BcKqBNDv+9grpueb/D394WnjxzJn6Zjzq7XcPRKNraeOmQuysdMgAkwASZgRoB9hBkQBx1yZ8FBIFGTh6x96Ug/mge9o3T2Vo+lOpVmI53qea6sTXtFNjIys6Fraovqaq/snGin0JFd2pUUpzEBxxLQ6xta1+/T60XJKVCngX7PgH5VmToHphLpRpx+Ydl0PNi2MpkM/v4+rdWSyWTSj7uNCvDDocuf4+m3f4G3P89EY7PhP+WFawU4/W1+qzzvDEECluxxXzfDTtsuVWcg6ikV3G9/uCAnJcA+ou98RB90FsqQLW4kpRtS860dN9L6ijKUlekGz413d/+5yjKQ+EIUon6WAU13stbSTUa6A7cs5FX0sPthqU7ZmxBF9fzzBWMtipAcMQNzI2cgfEuRMa7rzYU/i3YKHZuyu5bjVCbgSAK0/MhcH70ej14xSq9RpVkEeusQ/dian99Ic9FBd0yzCKYlSWPG+OOS7hrm/eU3+EXmu6iore5UX+eZXWAf0WsfYcGX6vOzpIGgrHyTv7DftksXnSW/ISXwHyYwuAmwj+i7Geg+6CxcwCZxIyndkJpvbb6RLsK2Z9RQq1cja3Bfm46tnclId+A2GyEBnlBHpiDPMMjo2DKhRtgzoVAqQxH1ZKCDdVtW98wzz+DLL7+0nMixTMACgTt3GltnFSwkg9LLy7WgV43SiL27u5slMZvjampq8PHHH+PIkSOoqqqymo9mOG7dugWNRgOdTmdVzlrCyJFe0Ls24af/egeLU/8beTdLrIni9NU8XK++ZTV96CRcYB/R05Nl8hEWfKnmUKI0EJR4yNQVUfe7badmsX0nChz6mwD5gKamZqvFUrojfcSNGzdw6NAh5OXlgX4Xx1rBzuIj+qCzYEK2EKnCgZITbQ3HV8O221EdtBUYvp+g13DKxC5nFxYqgbLMeCS+W9YHTOSY9eYFaLUX8NrMPlBvQeVTTz2FqKgonDlzxkIqRzkzgZ62jZ5TsCWv4ZV5jbaIWpQhw759+3b4+/uDbnr+8z//U9rfunUrKM0809mzZ/Gd73wHY8eOxU9+8hPzZJuOPynMwb/yztoke/Dr0zbJDQ2hhewj0Jef/rft1Bq270SBQ38T6C8f0djYiJUrV0KlUuH5559HSEgIpk2bhoKCAotNdhYf0YedBTmUAiYBbQ2j5ID+NLYlxCM+IRmna2D8FCHtZxS3Hun/P0WkJSFNui8+jWRJdiMy6FiMqmwUxxszxUFpOpLCQ6AOXo9W91lBumcjZLwa6kdikHxUyBlLELfbyPiveMT/VwbK9EVI/9lsSS4kPAnptPa+SYfTW2IwQ+QNCY9HykXTVK5JgR5F+9Zj7iNC9/gQzP6ZGOm3OpCoF7riRTvise2cKb9hW3ZovSH+jLl+Q7r0181PuhBVxG9KHDb9MliK1ujqpS2QjRTBIT4hRewZo8Qme6ehzBQ7B+0t5dNdTDHwNfJIzizqtCTM042YJGF2sGASPBtJB9rzFhWy8v3Nb36DH/3oR1i4cCGOHz9uRYqjmUAbAVsdgZuba6/efnT58mX89re/xcSJE5Gfn49r166Bbn5+/etfS8dtNQJo9uH1119Hfb3p/2X7VNv3F019Avf63GNThsxLZgbFplyDVUjOPkLY8R75CNj2sWTbQf7vV3MlX6cWdjtG1CFeCkY/a1It3DXIpy6dAbXwAzOWbsPpzj7PJN26ZfveioJ3+pFAf/mIlJQUvPXWW3jhhRdA/uK9995DUVER4uPjJZ/QvsnO5CP6sLPQHlm7ffkshI3KQsrOJMS8kS0l6MUNdNzmFKTqwxB5h9KyYFg9X4SsnSlCNhV51LGoyUOqOE49vhVzx0ch+XgeytSBhtmK/GSEqcOQuFPkbRJ9ki/TkPScGjM2GzQB9cj7u9C1PRkxU+9D1OYs5JWWIe94MqKejEJ8ZCDCXk5DthQnOiyPxCGDygR9dMiIDcR9Lwhj+qW4yW8S9docj5DA+HYyJGcKcoSO0op6ixvu3e0XUhUh9ZcbRbwGflPIEpvku9qKTszJPCEgR/hM07yMxsglC6YJZyEAzUnRPsEny/pKBhLrFDrl+zQRgVPjBV8DO222aEdkDFKK22eVI+tltWCSjKz8MpTlZyF5YRjWX2wvY32fHEpCQgIWLFiAjIwM64KcMuwJ0PRxS0uLTRxGjlTYJGdNiIz/zZs3ERcXh8mTJ0szBomJiaisrOw0cvT222/jo48+wpo1a+Dl5WVNZbfxri4uWDlrbrdyJPD1jW9RUuXk067sI+z0EXRlWA6dbHtNBuLV9yFKDJrpQ+cifFQu0oTPSHl3Pw5nnkKRvp2eim2YHSB86vvZKBN+Mfv9RITFpnUaNGqXo3WX7XsrCt7pBwL95SP0er209Ihmnukav//++6WBT/IRJ06cwKefftqhtUPTR3RoQutBH3YW0hAjRiNoRMIQ5mKb8WYz9HepWK0Eiv57NbYJI5TyBhmgcGx9IxLyeam4e2UTgqUqRuPw3bu4ezcX6yah9ZP3h43IW3MY2kaRlhUHlehaJC9OwukmJaL/qUW9RgNt/QW8NlGMwf8yGadbc4qdsizkhu5CYb3Iq92PaLmIK07HfmxALsU1XpDyQZ+G9JMiTXz1h1YjipYAzdwkZLTQaOqhTYsEdClI/pvl0XT54tVYLXTrd6Qgo0kooW9pBvbTzfS8GCz0pggr4eJ6hJnYefoh5hAQvPYwNjxjRd7B0dkZ+6EDEJ1eD02JBhqt2GoysFrwFNHGr5hVGLUap8rvivOjxf4fyEW8mLERMxBix6Yv/Wf76U9/ivnz52P//v025WGh4UdAr79jU6NdXGS9mlWgQmg5Ed34Hz16tPVZhevXr0udAUojGQpff/01fv/73+PZZ5/F008/3evZheeDH4Wbiyup7jYcK7Bz6rBbjQMlwD7CIT7C6CvCfkWDSl2fy7K/JSNFGPfA13OR+89dSD2Zja2PiTzecUgvOdzRxhfXI3R3IerJB+dtMPjkA4dtfo6Q7bvgyt9+IdBfPqKpqQm1tbXw9vaGUqmU2iaTySQfQMtUT548KcXRH2fzEX3YWSBcxlBRJkYmiqA33TS7zcKmtDgoxW180pNhSDojbobf3IW4cbDto1qH1D9GQulmFBc3+6l0Ez4xDnGP6Eb+yKQAAA/dSURBVFFWJsqrUCMsQpxMfRZOFRjlpE0wkt6IQ6BcHCjDED5LbMU3cs1qBFOcWyjCnhQR4ltvrG/WgTToxXFkQgz8qC1Cv/6RSISLuKyTF8RfC1+3cKx+JVAkpCFlH+UGyjLTRYuBhT9YCCpKJHb/NQrm7ViPTWeEle8+R68l1IEhko60NxKRcVEHPeRQqQRLKbbtT/QvN2DWKDpWIuyZMNpBXk73DksSNP55QUzlPfDAA8jJyTHG8MZWAsNFrrGxyaamyuUeNsl1JTRjxgzQkqNjx47h4YcfRnJyMjZt2oTly5dL61IpL61ZpaVK5Dg2bNgAek0rOQpK62nw9vDEE4EP2pT9fzWGGT+bhIeKENnVUvYRtvsIvfCpws+JwTYa9ZeCwc10ecbrdRopfVZosLQFVAi8X+zqMsz8pIibkoRNywMhF7sICke4tJONvA7+lBKtB7bv1tlwiuMI9JePkMvlGDVqFEpKSnD+/HmpAbQM1TTYWVpKa9oBZ/QRLlJr++RPNFJpVJoCjdibzQ7II17D+umAvlg4CPlqbF0baHstRqmhcmsnnnMB2XRYnIzZajXUxjB3R3c31yqou+2gFCHvC1IOZCS06Vbfn9jtCEtwwjpQXyR9Xzr04l/WIVqStBBR8+QGhdb+TtmAU8SNgvYu6nPEqI7+NDY+s17qbFjL5qh41fJUpC5WAee2Ye5UP3h6zkB8N88j0PMVsPOTm5srrfujGzQahbIzO4sPEwJkeG1pqqdn7zsLMpkMM2fOxOjRo1FYWIikpCTU1dVJz9dQp4DqkZ6eLs2Evfrqq3jkkUcoyiEhcvJMm/RcLCu2SW7wC0Wzj+joI2C7j9iEQhrxbxcK3zR1AKyf+cCIhdKy3bQ3NiJPL+Qq0pG6T2yVkQhrN3svYsy+KgR2mW4mLg7ZvgsI/O0XAv3lI8gH/PjHP4ZMJsP3v/99jBs3DgEBAThw4IAUZ2qsM/qIPuwsmLBZ2X6ajA2m2XR9KtLPWJGzJVodCHFrKwZJorH17/uxv0PYikgp0RZFlmTUEOqlhFmvmOsWxy/PkNIs/hkXhRia4j2wH+m6LBw+JKQWRHW9BEmImH/lU6IRN0XEdpolEXF98XVTIfrvGtRrLmDX2llQ6bORsjAYiR2X4/WqZJMjeeKJJ7Bnz55e6eLMzkugqakZLS13bWog/b6CTYJdCNGaU1oWt27dOmlp0V//+lc0NDRgzpw5oKVJNKK0fv16jBkzBrRulUaUKA+ppIfcMjMzpXx0bG+YOe5+m7IU3BL/Nxvv2CQ7pIXYRzj+9ImBqNS1SjEQtB4hnjLIAqKQ1jQLr2Wulwa24KAP23cHgWQ13RLobx9BvoBWQixevFiaZXjzzTdBDzlTRX19faVZhzYf4S8NLDmDjxiYzkJTNtb/aBt0YkbhWN4mBEOHbT9aj+wmGD4qNeyYZwCCQiAtginLhm7qQixc3D6EI9jboLZnf+UInR4oZc0uBcI76BblzFRJaZb/qBD38kKRlI7Dv8pAutiLXh4Nudja9a3IQtZFyhGK4Im0BTylTbspYX0esrOlyN7/0etBg05yVSji/ngKee+EA9Ah63QRHPExORL6T0dvFXCETtbhnARsnV6mtyDJZLJeQWhqasKf/vQn+Pj4IDo6Gh4eHoiJicHBgwfh4uKCv/zlL6B3a9MzDPQ66BUrVoAcBjkLKpjWq7700kvQ6XR0aHeY6DcGihG2WYe8m9/arX9IZWAf0TenqyAZqzfrEPmOBlqNBhqNFvWNp7DhMaXDymP77jCUrMgGAv3pI0zVodelfvDBB/jyyy+xatUqFBcXg5aiPvjgg6AXZDijj+jDzoL5w2tihH58EmghTtHmGGwsBma9uR7hQeuQskYYquKNiPmDcb27dyhCpZviNCTGbkP6++nIrjGdJgtb72hseDNUJORh/dQQoScN6fu2Yf3zIZi9pUzE9+4b/LOtiBZV1P8tCsFPJmHbvnSk/SEeYcGJyDJ1cNwAyc0XZCDleFuZpged07Zsgx7RiImwoS4FqUhKiEc8hednwDMgHvS+oFDBK9KN8ocjfB5t85A0b66Qi0FYYEjnNxEJ2U51cjN0M3AyBWn5pMM86JAeq0agsZ3p+9Kw/h06a/J2b2Myz2PfMa1jff7557F582b7MvahNKsenARabHwLkiNmFaizQOtP79y502F2gB5mc3d3l2YYyBnQ8iRyBqZgGlVatGgRvvjiC2kJU09pPmSaxuxGQUVddTcSQyGZfQSdpR75CMrYk3AlT1qyeyozFVknT+HUySxk7MtCXplO+KeeKOych+17ZyYc03cE+tNHUCuoU0A+gvYp3Lp1S1odoVQq8fjjj+Ohhx6SlrBev34dpuAMPqIPOwuArv3DV9K+BvribYj/uegUKFcjeaWKWGPWG6mIUwJ5v4zCRukGNhhJf44DpRa9m4iopVHY1uGVRlK2Dn+CX8nCqTcXijx5SPt5DKJeSMTGTK2oRBH0HSR7cKCMRGrOfsRNl6NMTI0nvhCFmJ+nIFuuRZno9EgaJy5E3GNiT5+FjZuz2sp0Czc+6AzIV8bBcLMv5Lr66rORvjMFKRQOZUMeFI51fy/EqVeCjbnkiH5zE2a5icP8DCGXBt0PDqNwd6SIaPe1VKcnRT1VQqY4Hev2WJqKUCJscRTU55JB7Yx6IQbbzskx6/Ush72NiX7g6o033hCV4C8T6JpAi41LkGjkv2tN3afSw2vz5s1DeXm59M7sr776ChTox9aoE/Hss8/C09NTWoJkei6Ktn5+fpJyLy8vqaPg6uoqHffkj8rboKu7vNq6rkZPuss9eNL70Ed0aqRT+YhOrbMxYs46bJop3OKBJOEjo4xhNkLUfvBUi0EpB1xWbN9tPBcs5hAC/ekjqML0PAI9p/Dyyy+DfsCTOgg0SPTqq6+CBpNoYImWqZJvMAU/J/ARLtR4x4ZIpLZ76Ip6YW0hFZETV+MYpWu3Gm52qXDvSOzS3hXTOLl4LYgiAOW8XdA01ktTpdrbd7FrjoiftA65lDdnnYVlSkrQMwWmPIbpVQ2OvT4LcpEVIse6nLtSGe1fwxq5h+LuIlUaqZcEYSkO4xZiV3Y97t7WiqlbDahO9dmpiG596CsQq0/fRX25SEuLNpZp0Kep0IgdOeIW03IesWvta2oftbFd0OYdw6bFgR10QszInKqvb+WT+8dIBC4/LNrXvi0W6kSsNYZ8eb8KlWpi3l7Vgl24UG9oi0Yj2iPKOfW7WVDC8DGXl2LplbdU5z1mHRYpseOfp59+umMEHzEBKwRabJxZcHGRWdFgXzT9vgK9/YiM//Tp0zFdhHPnzoGWGlGafdrsl/bzVNiUSaevtUlucApFso/orY+w4AMDX8mV7H+u9BY+w5k3t9Vl7yci6VwwNnyhkfwY2ffCL/Zj9RQhX5aCVPqNTJMf6lBGICz5T5Gr05fteyckHOEQApaV9LePmDp1qvQbPFu2bMHq1atx5coV0Fvx1q5dC5nMMX7IcksNsQPlI/qgs2BokEP+usmhVKmg9IYdHzkoj0ql7HhzDQd9vJVQdVEn+ai2+uprdCg7vh5JO/TAlA1Y94yD6mBSYyOf9nUyZJWDGCkNvShY+1A+FbW1Gzlr+TmeCfSWQIuNMwsymWNMGY0K0cPNt2/flp5PoGcUaFbhlVdeAaVZag/NRtCAiGmq2ZKMrXG+nt42ierqa2ySc3ohG21gRw5ykP1TDQcfgfafIqRuzwJUkQifrpL8GNn3wJnhCB1PcoEIDKQtByYwdAj0t4+gV72fPXsWWq1Wek0//VDba6+9ZtU/EEln8BGO8bBEg0NHAjVpiBrpB3X4RmQjFJv2WZoN6ZjFWY64HUzAUQT8/EZi7NiAboNC4dgeLS0lotenUqB99NNnTdg8FP5id7fhF08v7qcacTF9RqDffUQgIiNEb6AsGWGBsxGTEA96Lm5usB/iM4HANbuQRDMMfdZgVswEHE9goHyEUqmUlqRaG0RyfEsNGgfKR3BnwcDf8X/1wVj4ehxe234YF8ovYF0Q+MMEmAATGIoEuM59QWAAfETw73JRmLEJcfdrkJV5GIczLwARm7A/W4vCP4dDCf4wASbABDoT4M5CZyaOiRkVirjf7cKGlZEIHQX+MAEmwASYABNoIzAgPkKOwIh12JWVCw396GfJBRz+4zosnM7dhLYTMxz2uI1MwD4C3FmwjxdLMwEmwASYABNgAkyACTCBYUOAOwuD/FRz9ZgAE2ACTIAJMAEmwASYwEAR4M7CQJHncpkAExiOBLjNTIAJMAEmwASGFAGLnQV6DeCQagVXlgkwASbABLol4Cjb7ig93VaYBZjAoCfAFWQCzkPAmm3v1FlwdXWBre+tdR483BImwASYgPMTINtONr43LaX8pKc3OjgvE2ACTIAJDD4CZNvJxpvXrFNnwd3dDQ0Nd8zlnOKYG8EEmAATGM4EyLaTje8NA8pPenqjg/MyASbABJjA4CNAtp1svHnNOnUW5HIP6PUN5nJ8zASYABMYbAS4PnYSINtONt7ObB3EKT/p6RDJB0yACTABJjDkCZBtJxtv3pBOnQUvLzkaG5vE7EKjuSwfMwEmwASYwBAl0NDQKNl2svG9aQLlZx/RG4Kc1zoBTmECTGCgCHTlIzp1FqiSI0cqUF1dA2sPOpAMBybABJgAExgaBMiWk00n2+6IGpMe0kd6HaGPdTABJsAEmMDAESBbTjadbLulWljsLNDI0YgR7tBqq612GCwp4zgmwASYABMYXATICZAtJ5tOtt0RtSM9pI/0kn5H6GQdTIAJMAEm0P8EyIaTLSebTrbdUg0sdhZI0NfXG66urqio0PGSJALCgQk4NwFunRMSoGllsuFky8mmO7KJpI/0kn4qx5G6WRcTYAJMgAn0PQGy3WTDyZaTTbdWotXOAmWgjAqFJ3S6alRWVqGuTo/m5haebSA4HJgAE2ACg4wAjRCRjSZbTTabbDfZcLLlfVFV0kv6qRwqj8ql8qkefVEe67SHAMsyASbABDoSINtMNppsNdlsst1kw8mWd5TseNRlZ4FEaUpizJh7QE9H01PSFRVaaDQVuH69nAMz4GuArwG+BgbRNUC2mWw02Wqy2WS7yYaTLe+rQPqpHCqPyqXyqR7sI9hH8jXA1wBfAw68Bhzga8g2k40mW002m2w32fDu/EO3nQWTAlLm7+8LUjx2bAA4MAO+Bvga4Gtg8F0DZKPJVpPNNtnv/thSeVQulc/XxeC7Lvic8Dnha4CvAboGyEaTrSabbatvsLmzYKtClmMCTACMgAkwASbABJgAE2ACTkGAOwtOcRq5EUyACTABJtB3BFgzE2ACTGD4EuDOwvA999xyJsAEmAATYAJMgAkMPwLcYrsIcGfBLlwszASYABNgAkyACTABJsAEhg+B/wMAAP//+S4nvwAAAAZJREFUAwBHmLN5pZDWQQAAAABJRU5ErkJggg==" width="624" height="61" alt="ANVS's Sentiment Meter and Message Volume as of 12:06 p.m. ET on Nov. 18, 2025 | Source: Stocktwits"><figcaption>ANVS's Sentiment Meter and Message Volume as of 12:06 p.m. ET on Nov. 18, 2025 | Source: Stocktwits</figcaption></figure>ANVS stock fell 31% this year and by 49% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/waymo-announces-robotaxi-launch-in-five-more-cities/cLPV4fyRE7M">Waymo Announces Robotaxi Launch In Five More Cities</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Global stock market chart and trading board - stock photo

Annovis Stock Rises After Company Confirms Meeting With Regulators To Discuss Drug In Treating Parkinson's Disease Dementia

The meeting with the FDA is scheduled for January 2026. 

<ul class="summary-bullets"><li>The strategic review comes after Neuphoria discontinued advancing its lead drug candidate called BNC210 for the treatment of social anxiety disorder in October.</li><li>Strategic alternatives under consideration may include, but are not limited to, mergers, acquisitions, partnerships, joint ventures, licensing arrangements, or other strategic transactions, the company said.</li><li>The company said it will carefully evaluate and consider Lynx1 Master Fund’s indication of interest in connection with its review of strategic alternatives.</li></ul> Neuphoria Therapeutics Inc. (NEUP) initiated a review of strategic alternatives, including potential acquisitions, on Tuesday to advance its pipeline programs and maximize shareholder value.NEUP shares traded 4% higher in the pre-market session at the time of writing.<h2 class="st-heading-2">Strategic Alternatives Under Consideration</h2>Strategic alternatives under consideration may include, but are not limited to, mergers, acquisitions, partnerships, joint ventures, licensing arrangements, or other strategic transactions, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.neuphoriatx.com/news-releases/news-release-details/neuphoria-announces-initiation-strategic-review-maximize">said.</a>The company added that it does not have a defined timeline for exploring strategic alternatives. Further, it is not confirmed that the process will result in a transaction.The strategic review comes after Neuphoria discontinued advancing its lead drug candidate called BNC210 for the treatment of social anxiety disorder in October after a late-stage trial missed its primary and secondary endpoints. Neuphoria then also said it will assess new development paths for BNC210 as a treatment for post-traumatic stress disorder (PTSD).<h2 class="st-heading-2">Lynx1 Master Fund Expresses Interest</h2>Neuphoria on Tuesday also added that it received an unsolicited non-binding indication of interest from Lynx1 Master Fund LP earlier this week to acquire all of the outstanding shares of Neuphoria that it does not already own for $5.20 per share in cash. The company said it will carefully evaluate and consider this indication of interest in connection with its review of strategic alternatives.Lynx1 Master Fund LP also expressed intent to nominate certain individuals to stand for election to Neuphoria’s Board of Directors at the company’s 2025 Annual Meeting of Stockholders, the company said. Neuphoria’s Board of Directors will now review the proposed director nominees. The annual meeting is scheduled for December 12.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NEUP">NEUP stock</a> jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.<figure class="image"><img style="aspect-ratio:623/62;" src="data:image/png;base64,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" width="623" height="62" alt="NEUP's Sentiment Meter and Message Volume as of 8:28 a.m. ET on Nov. 11, 2025 | Source: Stocktwits"><figcaption>NEUP's Sentiment Meter and Message Volume as of 8:28 a.m. ET on Nov. 11, 2025 | Source: Stocktwits</figcaption></figure>NEUP stock is up by 43% this year and by 11% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/poet-technologies-and-quantum-computing-team-up-to-boost-ai-data-speeds/cLPdoHVREPl">POET Technologies And Quantum Computing Team Up To Boost AI Data Speeds</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

NEUP Shares Rise Pre-Market As It Explores Strategic Alternatives, Including Potential Acquisition

Neuphoria also added that it received an unsolicited non-binding indication of interest from Lynx1 Master Fund LP earlier this week to acquire all of the outstanding shares of Neuphoria that it does not already own for $5.20 per share in cash. 

Vanguard Group, Inc. - Vanguard Extended Market Index ETF

Up more than 2%

Up 0–2%

Flat to down 2%

Down more than 2%

The S&P 500 is modestly lower so far in December, putting the Santa Claus rally in question. The Santa Claus rally refers to the market’s tendency to rise in the final weeks of the year—what do you expect from December 16 through December 31?

What do you expect the S&amp;P 500’s total return to be in the second half of December?

Stocktwits

What do you expect the S&P 500’s total return to be in the second half of December?

VXF
Vanguard Extended Market ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest VXF News

VXFVanguard Extended Market ETF